

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

f **SHARE** (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=018932)

t **TWEET** (HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=018932)

+

✉ **EMAIL** (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=018932)

[Home \(index.cfm?resetfields=1\)](#) | [Back to Search Results](#)

Product Details for NDA 018932

REVIA (NALTREXONE HYDROCHLORIDE)
50MG

Marketing Status: Discontinued

Active Ingredient: NALTREXONE HYDROCHLORIDE

Proprietary Name: REVIA

Dosage Form; Route of Administration: TABLET; ORAL

Strength: 50MG

Reference Listed Drug: No

Reference Standard: No

TE Code:

Application Number: N018932

Product Number: 001

Approval Date: Nov 20, 1984

Applicant Holder Full Name: TEVA WOMENS HEALTH INC

Marketing Status: Discontinued

[Patent and Exclusivity Information \(patent_info.cfm?](#)

[Product_No=001&Appl_No=018932&Appl_type=N\)](#)